Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2026Pharmacoepidemiology and Drug SafetyOpen Access

Comparative Analysis of Potential Side Effects of Targeted Oral Hypoglycemic Agents Using Spontaneous Adverse Event Reports and Social Media Data

View Full Paper
Ask AI
Bookmark
Share

Authors

SOSe‐Hoon OhDPDong-Young ParkYSYun‐Kyoung Song

Discussion

Loading...

Member takes

Overview

Analysis reveals differing side effects for oral hypoglycemic agents in tweets and FDA data, suggesting better patient awareness is needed.

Key Points

  • The research aims to compare adverse events related to oral hypoglycemic agents using social media and FDA reporting data.
  • Collected adverse event data from tweets and the FDA Adverse Event Reporting System from 2017-2021.
  • Annotated and labeled relevant sentences in tweets for analysis.
  • Categorized data according to the Medical Dictionary for Regulatory Activities System Organ Class.
  • Both drugs exhibited high-frequency similarities in adverse event categories.
  • DPP4 inhibitors showed a notable difference in cardiac disorders between the two datasets.
  • SGLT2 inhibitors had significant differences in the Surgical and medical procedures category.

Cite This Study

Oh et al. (2026) studied this question.

synapsesocial.com/papers/69fbef68164b5133a91a349chttps://doi.org/10.1002/pds.70386
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data2026
  2. 2Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 20232024 · 3 citations
  3. 3SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system2021 · 66 citations
  4. 4Cardiovascular safety signals with dipeptidyl peptidase‐4 inhibitors: <scp>A</scp> disproportionality analysis among high‐risk patients2018 · 14 citations
  5. 5Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions2018 · 20 citations